^
    1year
    A Phase 2 Study of a Novel Immunotherapy SL-701 in Adults With Recurrent Glioblastoma: Exploring the Prognostic Value of Treatment-Induced CD8+CD57+ T-cells as a Marker for Survival. (SNO 2023)
    In this study, we present updated findings from a phase 2 clinical trial (NCT02078648) evaluating SL-701+poly-ICLC+bevacizumab, where the 12-month overall survival (OS) was 50%. These qualitative differences in the immune response, detectable as early as week 8 post treatment, may serve as biomarkers for monitoring and predicting survival. Deep sequencing of SL-701-specific T-cells is planned.
    Clinical • P2 data • IO biomarker
    |
    CD8 (cluster of differentiation 8) • BIRC5 (Baculoviral IAP repeat containing 5) • CD4 (CD4 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
    |
    LAMP1 expression
    |
    Avastin (bevacizumab) • Hiltonol (poly-ICLC) • SL-701
    almost3years
    Phase 2 study of SL-701, a novel immunotherapy, in adults with recurrent GBM: A high parameter flow cytometry analysis of CD8+ T cells and potential implications for patient enrichment strategies (SNO 2021)
    In stage 2 (SL-701 + bevacizumab + poly-ICLC) the overall survival at 12 months was 50%. By week 24, SL-701-induced target-specific CD8+ T cells expressing IFNg were detected in 8 of 27 patients (30%) who had sufficient samples, with co-expression of PD-1, TIM3, and LAG3 detected in 4 patients. To further understand the T-cell response to SL-701, deep sequencing of target-specific CD8+ T cells using whole transcriptome-based molecular cytometry and high parameter (25+ color) flow cytometry is currently underway and updated data will be reported.
    Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    PD-1 expression • CD8 expression • HAVCR2 expression • IFNG expression
    |
    Avastin (bevacizumab) • Hiltonol (poly-ICLC) • SL-701